For progression-free survival, the loss of expression of multiple SWI/SNF subunits, FIGO staging, residual tumor size and complication with thromboembolism were significant prognostic factors (p=0.0038, p<0.0001, p<0.0001 and p=0.0008, respectively; Table 3). The gene discussed is SMARCA1; the disease is neoplasm.